Patents by Inventor Gregory Springett

Gregory Springett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiosemicarbazones inhibitors of lysophosphatidic acid acyltransferase and uses thereof
    Patent number: 9622993
    Abstract: Lysophosphatidic acid acyltransferase-beta (LPAAT-?) catalyzes the production of phosphatidic acid (PA) from lysophosphatidic acid (LPA). The lipid cofactor PA contributes to the activation of c-Raf, BRAF, mTOR and PKC-?. LPAAT-? expression is a prognostic factor in gynecologic malignancies and is being investigated as a therapeutic target in a variety of tumor types. A class of thiosemicarbazones was identified as inhibitors of LPAAT-? from a screen of a library of small molecules. A focused library of thiosemicarbazones derivatives was prepared and led to the development of compounds which potently inhibit LPAAT-? and inhibit the growth of MiaPaCa2 human pancreatic cancer cells.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: April 18, 2017
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Gregory Springett, Said M. Sebti, Nicholas J. Lawrence
  • THIOSEMICARBAZONES INHIBITORS OF LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE AND USES THEREOF
    Publication number: 20170027893
    Abstract: Lysophosphatidic acid acyltransferase-beta (LPAAT-?) catalyzes the production of phosphatidic acid (PA) from lysophosphatidic acid (LPA). The lipid cofactor PA contributes to the activation of c-Raf, BRAF, mTOR and PKC-?. LPAAT-? expression is a prognostic factor in gynecologic malignancies and is being investigated as a therapeutic target in a variety of tumor types. A class of thiosemicarbazones was identified as inhibitors of LPAAT-? from a screen of a library of small molecules. A focused library of thiosemicarbazones derivatives was prepared and led to the development of compounds which potently inhibit LPAAT-? and inhibit the growth of MiaPaCa2 human pancreatic cancer cells.
    Type: Application
    Filed: April 7, 2015
    Publication date: February 2, 2017
    Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Gregory Springett, Said M. Sebti, Nicholas J. Lawrence